LifeBond

Company Overview

Snapshot

Founded in January 2007 by Orahn Preiss-bloom and Ishay Attar, LifeBond operated with 11–50 employees. The company raised a total of $56.5M across 5 funding rounds from 5 investors. LifeBond was acquired by Bard Medical in January 2020.

Business overview

LifeBond develops and manufactures medical devices focused on biosurgery and tissue repair to prevent postoperative complications. The company's product pipeline utilizes 100% natural biosurgical materials with established safety profiles. Its first product, LifeSeal Surgical Sealant, is designed to reinforce surgical sites and minimize staple-line leakage in bariatric and colorectal procedures. LifeBond's second product, LifeMesh Self-Fixating Mesh, provides secure surgical mesh fixation for hernia repair, aiming to reduce postsurgical complications associated with penetrative mesh fixation. The company operates within the Health Tech & Life Sciences sector, specifically in Medical Devices and Biomaterials & Tissue Engineering, serving the healthcare industry in Europe and the United States.

Strategic signal

In January 2020, LifeBond was acquired by Bard Medical. This acquisition highlights the strategic value of LifeBond's biosurgery and tissue repair technologies, signaling a successful exit for investors and a validation of the company's innovative approach to reducing postoperative complications in the medical device market.

Company Intelligence Q&A

What was LifeBond's exit event?

LifeBond was acquired by Bard Medical in January 2020. The financial terms of the acquisition were not disclosed.

When did LifeBond receive its last disclosed funding?

LifeBond received its last disclosed funding in August 2015. The round involved investors such as Aurum Ventures M.K.I and Giza Venture Capital.

What was a key product development for LifeBond in 2016?

In April 2016, LifeBond obtained CE approval for its surgical product, LifeSeal, which also received FDA fast-track status.

What was the focus of LifeBond's multi-center international study in 2017?

In February 2017, LifeBond's multi-center international pivotal study of the LifeSeal Surgical Sealant for GI resections was actively enrolling patients in the US and Europe.

Which investors participated in LifeBond's Series A funding round?

In September 2007, LifeBond secured Series A funding from investors including The Zitelman Group.